Core Viewpoint - The establishment and development of the Sci-Tech Innovation Board (STAR Market) in China have shown significant progress, with a focus on supporting technological innovation and enhancing the quality of listed companies [2]. Group 1: Market Development - The STAR Market has evolved from inception to a robust platform, maintaining steady growth and effectively fulfilling its market functions [2]. - The introduction of policies such as the "Eight Measures for the STAR Market" and "Six Measures for Mergers and Acquisitions" by the China Securities Regulatory Commission (CSRC) has facilitated this development [2]. Group 2: Reform Initiatives - The implementation of the "1+6" reform in June has progressed smoothly, establishing a growth tier for the STAR Market and introducing experienced institutional investors and pre-review systems [2]. - The CSRC aims to deepen comprehensive reforms in investment and financing, enhancing the inclusiveness, adaptability, attractiveness, and competitiveness of the STAR Market [2]. Group 3: Future Directions - The CSRC plans to align with the spirit of the 20th National Congress of the Communist Party of China, focusing on strategic tasks and major initiatives for the capital market during the 14th Five-Year Plan period [2]. - There is a commitment to improving the quality of listed companies, strengthening regulation, and protecting investors, which will contribute to the high-quality development of the STAR Market [2].

Core Viewpoint - The article discusses the successful listing of the first batch of new registered companies in the Sci-Tech Innovation Board's growth layer, highlighting the significance of recent reforms and policies aimed at supporting high-quality development in the technology sector [2][4][7]. Group 1: Listing of New Companies - On October 28, three companies, He Yuan Bio, Xi'an Yicai, and Bibete, officially listed on the Sci-Tech Innovation Board, marking a historic moment for the growth layer [2][9]. - The market response was enthusiastic, with He Yuan Bio opening up 202%, Xi'an Yicai 361%, and Bibete 175% on their debut [9]. Group 2: Regulatory and Policy Framework - The China Securities Regulatory Commission (CSRC) has introduced significant policies such as the "Eight Articles for Sci-Tech Innovation Board" and the "Six Articles for Mergers and Acquisitions" to enhance the regulatory framework [2][4]. - The Sci-Tech Innovation Board aims to support "hard technology" companies by implementing a more inclusive and adaptable regulatory environment, focusing on sectors like artificial intelligence and commercial aerospace [6][7]. Group 3: Future Directions and Investor Engagement - The focus will be on enhancing corporate governance, improving development quality, and increasing investor returns, with a strong emphasis on investor protection [4][6]. - The establishment of the growth layer is intended to provide more inclusive capital market support for unprofitable technology companies, fostering a positive cycle between technology, industry, and finance [15][16]. Group 4: Market Participation and Investor Accounts - As of now, 758 million investor accounts have been opened for trading in the growth layer, representing 126% of the total active investor accounts [15]. - The recent reforms have led to the acceptance of 26 new companies, including 8 unprofitable firms, indicating a growing interest in supporting innovative enterprises [16].

Core Viewpoint - Shanghai is committed to leveraging the "1+6" policy opportunities of the Sci-Tech Innovation Board to enhance its international technology innovation center capabilities and create a world-class investment and financing ecosystem, promoting high-tech and innovative enterprises to enter the market and grow stronger [1] Group 1: Policy and Institutional Framework - The establishment of the Sci-Tech Innovation Board and the pilot registration system serves a dual mission of capital market reform and supporting technological self-reliance [1] - Over the past six years, the Sci-Tech Innovation Board has nurtured a number of high-growth technology companies and developed replicable and promotable reform experiences [1] - The "1+6" policy released at the Lujiazui Forum this year, following last year's "Eight Measures for the Sci-Tech Innovation Board," injects strong momentum into the new journey of the board as it turns six [1] Group 2: Strategic Initiatives - Shanghai aims to accelerate the establishment of a globally influential technology innovation hub, utilizing the collaboration mechanism with the China Securities Regulatory Commission to deepen the reform of the Sci-Tech Innovation Board [1] - The upgraded "Pudong Light" initiative and other measures will leverage Shanghai's advantages as a global innovation center and modern industrial system to connect "hard technology" enterprises with the capital market [1] - The city is committed to fulfilling its responsibility in serving national strategic needs through these initiatives [1]

Core Points - The first batch of new registered companies in the Sci-Tech Innovation Board's growth tier, including Xian Yicai, Heyuan Bio, and Bibet, officially listed on October 28, marking a significant milestone for the board [1][4][7] - The listing increased the total number of companies in the growth tier to 35 and the total number of listed companies on the Sci-Tech Innovation Board to 592 [1] - The initial offering prices for the three companies were 8.62 CNY, 29.06 CNY, and 17.78 CNY per share, with significant price increases observed by midday trading on the listing day [1] Company Summaries - Xian Yicai's stock price rose to 26.74 CNY, reflecting a 210.21% increase from its offering price [1] - Heyuan Bio's stock reached 88.04 CNY, marking a 202.96% increase [1] - Bibet's stock price climbed to 34.44 CNY, showing a 93.7% increase [1] Regulatory and Policy Insights - The Vice Chairman of the China Securities Regulatory Commission (CSRC), Li Chao, emphasized the importance of utilizing reform policies to enhance development quality and investor returns [5][7] - Li noted that the establishment of the growth tier represents a solid step forward in capital markets supporting technological innovation and new productive forces [7] - The CSRC has implemented several significant policy measures, including the "1+6" reform framework, to facilitate the growth of high-tech enterprises [8] Government Support and Future Directions - Shanghai's Vice Mayor, Wu Wei, highlighted the city's commitment to building a world-class investment and financing ecosystem for "hard tech" companies [9][11] - Wu stated that the Sci-Tech Innovation Board has successfully nurtured a number of high-growth technology companies and has created replicable reform experiences [11] - The government aims to enhance the international competitiveness of Shanghai as a technology innovation hub [12] Market Dynamics and Future Outlook - The Shanghai Stock Exchange's Chairman, Qiu Yong, indicated that the board will continue to support "hard tech" companies with a focus on high standards and effective regulation [13][15] - The market is expected to see a continued influx of innovative companies as the regulatory environment becomes more accommodating [15][19] - The integration of technology, finance, and industry is anticipated to foster a virtuous cycle that supports sustainable economic growth [18][22]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) aims to deepen comprehensive reforms in the capital market to enhance its inclusiveness, adaptability, attractiveness, and competitiveness, thereby better serving the "14th Five-Year Plan" development goals and the construction of a financial power [1][7]. Group 1: Market Developments - The first batch of new registered companies in the Sci-Tech Innovation Board's growth layer was listed on October 28, marking a significant advancement in the board's reform and development [1]. - Three unprofitable companies, He Yuan Biological-U (688765.SH), Xi'an Yicai-U (688783.SH), and Bibete-U (688759.SH), collectively went public [1]. - As of now, the number of companies in the Sci-Tech Innovation Board's growth layer has reached 35, with a total of 592 listed companies on the board [6]. Group 2: Regulatory and Institutional Support - The CSRC has successfully implemented the "1+6" reform policy since June, which includes the introduction of professional institutional investors and pre-review systems [5]. - The Shanghai Municipal Government is actively collaborating with the CSRC to enhance the operational stability and functionality of the Sci-Tech Innovation Board [5]. - The Shanghai Stock Exchange (SSE) has completed preparations for rules, technology, and market readiness within four months following the reform policy's release [6]. Group 3: Future Plans and Strategic Focus - The CSRC plans to research and formulate strategic tasks and major initiatives for the capital market during the "14th Five-Year Plan" period, focusing on risk prevention, strong regulation, and promoting high-quality development [7]. - The SSE will focus on four key areas: maintaining the "hard technology" positioning, promoting development through reform, enhancing regulatory effectiveness, and prioritizing investor protection [8].

Core Insights - The China Securities Regulatory Commission (CSRC) is accelerating the planning for the capital market development in the next five-year period, focusing on risk prevention, strong regulation, and promoting high-quality development [1] - The CSRC aims to deepen comprehensive reforms in capital market investment and financing, enhancing the inclusiveness, adaptability, attractiveness, and competitiveness of China's capital market [1] Group 1: CSRC's Strategic Focus - The CSRC is committed to implementing a new round of capital market reform and opening up, with a focus on improving the coordination between investment and financing functions [1] - The CSRC emphasizes the importance of a robust regulatory framework to support high-quality development in the capital market [1] Group 2: Role of the Sci-Tech Innovation Board - The Sci-Tech Innovation Board (STAR Market) is increasingly demonstrating its role as a "testing ground" for reforms, leading to continuous improvements in the foundational systems of the entire market [2] - The CSRC encourages companies listed on the STAR Market to fully utilize reform policies to enhance corporate governance and improve development quality and investor returns [2] Group 3: New Listings on the STAR Market - The first three newly registered companies in the Sci-Tech Growth Layer officially listed on the STAR Market, just over four months after the CSRC announced the establishment of this layer [3] - Among the first three companies, two are high-tech firms in the biopharmaceutical sector, and one is in the semiconductor materials sector, all of which are currently unprofitable [3] - In 2023, the STAR Market has seen 11 companies listed, raising a total of 16.95 billion yuan in IPO financing, representing a 54% year-on-year increase [3]

Core Viewpoint - The role of the Sci-Tech Innovation Board as a "testing ground" for reforms is increasingly evident, supporting high-tech enterprises in fields such as integrated circuits and biomedicine, and accelerating the gathering of strong momentum for technological innovation [1] Group 1 - The first batch of newly registered companies on the Sci-Tech Innovation Board has been listed [1] - The China Securities Regulatory Commission (CSRC) Vice Chairman Li Chao emphasized the continuous improvement of the market's foundational systems [1] - The Sci-Tech Innovation Board is effectively supporting a number of high-tech enterprises [1]

Group 1 - The core message emphasizes the importance of enhancing the inclusiveness, adaptability, attractiveness, and competitiveness of China's capital market as outlined by the Chairman of the China Securities Regulatory Commission (CSRC), Wu Qing [1][2] - The CSRC plans to support emerging industries by implementing reforms in the Growth Enterprise Market (GEM) and establishing listing standards that cater to innovative enterprises in new sectors [1][2] - The introduction of the "Qualified Foreign Institutional Investor (QFII) Optimization Work Plan" aims to facilitate foreign investment by improving access management, operational efficiency, and expanding investment scope [1][2] Group 2 - The reform of the Sci-Tech Innovation Board (STAR Market) is accelerating, with the first batch of newly registered companies set to list, supported by measures such as the introduction of professional institutional investors [2] - Institutional reforms will focus on streamlining refinancing processes, expanding merger and acquisition support channels, and encouraging listed companies to enhance governance and return value to shareholders through dividends and buybacks [2] - The development of the Beijing Stock Exchange (BSE) will be promoted, along with the implementation of pioneering policies [2]

Group 1: Core Views - Three companies, Xian Yicai, Heyuan Bio, and Bibet, were listed on the Shanghai Stock Exchange on October 28, marking the first batch of companies in the newly established Sci-Tech Innovation Board Growth Tier [1] - The total number of companies in the Sci-Tech Innovation Board has reached 592, with 35 in the Growth Tier, reflecting the board's commitment to supporting hard technology enterprises [1] Group 2: Heyuan Bio - Heyuan Bio's new plant in Wuhan is set to produce 120 tons of raw liquid annually, with its recombinant human serum albumin injection approved for market entry, becoming the first of its kind in China [2][3] - The company aims to revolutionize the global albumin market with its "rice blood-making" technology, which eliminates reliance on plasma extraction [4][5] - Heyuan Bio has achieved a purity level of 99.9999% for its recombinant human serum albumin, significantly improving production efficiency and safety [6][7] Group 3: Bibet - Bibet, a biopharmaceutical company focused on oncology and metabolic diseases, was also listed on the Sci-Tech Innovation Board, emphasizing its commitment to source innovation [9][10] - The company is advancing its global first-in-class drug, BEBT-908, which targets difficult-to-treat lymphoma patients, and is in the process of accelerating its clinical trials [11][12] - Bibet has developed a comprehensive platform for siRNA drug development, with multiple projects in various clinical stages, showcasing its innovative capabilities [12][13] Group 4: Xian Yicai - Xian Yicai, a key player in the semiconductor materials sector, has become the first unprofitable company to be listed on the Sci-Tech Innovation Board, highlighting the board's support for hard technology firms [17][18] - The company has achieved significant production capacity in 12-inch silicon wafers, ranking first in China and sixth globally, and aims to enhance the competitiveness of China's semiconductor industry [19][20] - Xian Yicai plans to raise 4.9 billion yuan through its IPO to expand its production capacity and accelerate technological advancements, with a goal of reaching 1.2 million wafers per month by 2026 [23][24]

证监会主席吴清表示，纵深推进板块改革，增强多层次市场体系的包容性和覆盖面，10月28日科创板科 创成长层将迎来首批新注册企业上市，试点引入资深专业机构投资者、预先审阅等已经实施，改革效应 正加快显现，证监会还将启动实施深化创业板改革。除了关于深化创业板改革之外，吴清还在会上透露 将发布《关于加强资本市场中小投资者保护的若干意见》（以下简称《若干意见》），当晚，中小投资 者保护"23条"如期而至。 纵深推进创业板改革 10月27日，吴清重磅宣布将启动实施深化创业板改革。 吴清表示，纵深推进板块改革，增强多层次市场体系的包容性和覆盖面。将启动实施深化创业板改革， 设置更加契合新兴领域和未来产业创新创业企业特征的上市标准，为新产业、新业态、新技术企业提供 更加精准、包容的金融服务。 16年前，即2009年10月30日，创业板首批28只个股集体亮相，创业板开市。伴随着资本市场全面注册制 的推进，创业板也从核准制走向注册制。历经16年的发展，创业板也培育了不少龙头企业，包括宁德时 代、东方财富、新易盛、阳光电源等。 经统计，目前创业板市场共有1389只个股，合计总市值逼近18万亿元。 科创板改革效应正加快显现 北京商报 ...